The International Cohort Consortium of Infectious Disease (RESPOND
) was formed in 2017 as a prospective, multi-cohort collaboration for the study of infectious diseases, with a special focus on people with HIV.
RESPOND was founded upon the groundwork laid by outstanding European HIV cohort collaborations such as EuroSIDA, the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) and Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) studies, and utilizes a similar, well-established infrastructure.
19 cohorts are currently involved in the RESPOND consortium with over 30,000 individuals are under active follow up.
RESPOND offers a research framework with a flexible organization, applying a common data model across different substudies, utilizing one shared data pool. Additionally, all involved in RESPOND can contribute to the ongoing scientific agendas. Together, these dynamic features facilitate responses to a broad range of unmet research needs.
The large size of RESPOND consortium and a heterogeneous study population with participants from across the whole of Europe and Australia and a high degree of data quality — including the central validation of standardized clinical event definitions
— ensure that the results are reliable and applicable to a broader population of people with HIV.
RESPOND aims to address clinically relevant research questions, including the risk and outcomes of non-AIDS comorbidities and the possible relationship to long-term ART exposure; to the outcomes and treatment of viral hepatitis B (HBV), hepatitis C (HCV), and tuberculosis (TB) co-infections; and to support public health initiatives.
The consortium is an open network that welcomes additional cohorts to join if predefined criteria regarding the inclusion
of a minimum number of participants, the need for a designated data manager, and data quantity and quality are met.
For more information about RESPOND, please contact the Coordinating Centre at: firstname.lastname@example.org